Phase 3 Recruiting Academic/Other
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …
Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Illinois: - Alton Memorial Hospital — Alton, Illinois
- Advocate Outpatient Center - Aurora — Aurora, Illinois
- Advocate Good Shepherd Hospital — Barrington, Illinois
- Illinois CancerCare-Bloomington — Bloomington, Illinois
- Illinois CancerCare-Carthage — Carthage, Illinois
Phase 3 Recruiting Academic/Other
This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tum…
Sponsor: NRG Oncology
NCT ID: NCT04134260
Sites in Illinois: - Alton Memorial Hospital — Alton, Illinois
- Rush-Copley Medical Center — Aurora, Illinois
- Advocate Outpatient Center - Aurora — Aurora, Illinois
- Advocate Good Shepherd Hospital — Barrington, Illinois
- Illinois CancerCare-Bloomington — Bloomington, Illinois
Phase 3 Recruiting Network
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation ther…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04423211
Sites in Illinois: - Alton Memorial Hospital — Alton, Illinois
- OSF Saint Anthony's Health Center — Alton, Illinois
- Rush-Copley Medical Center — Aurora, Illinois
- Illinois CancerCare-Bloomington — Bloomington, Illinois
- Illinois CancerCare-Canton — Canton, Illinois
Phase 3 Recruiting Network
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in Illinois: - Rush - Copley Medical Center — Aurora, Illinois
- Illinois CancerCare-Bloomington — Bloomington, Illinois
- Illinois CancerCare-Canton — Canton, Illinois
- Illinois CancerCare-Carthage — Carthage, Illinois
- Northwestern University — Chicago, Illinois
Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Illinois: - University of Illinois — Chicago, Illinois
- Elmhurst Memorial Hospital — Elmhurst, Illinois
- Edward Hospital/Cancer Center — Naperville, Illinois
- Edward Hospital/Cancer Center?Plainfield — Plainfield, Illinois
- Memorial Hospital East — Shiloh, Illinois
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary s…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06931340
Sites in Illinois: - Illinois CancerCare-Bloomington — Bloomington, Illinois
- Illinois CancerCare-Canton — Canton, Illinois
- Illinois CancerCare-Carthage — Carthage, Illinois
- Centralia Oncology Clinic — Centralia, Illinois
- Rush MD Anderson Cancer Center — Chicago, Illinois
Phase 3 Recruiting Network
This phase III trial compares the effect of adding carboplatin to the standard of care chemotherapy drug cabazitaxel versus cabazitaxel alone in treating prostate cancer that keeps growing even when the amount of testosterone in the body i…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06470243
Sites in Illinois: - Illinois CancerCare-Bloomington — Bloomington, Illinois
- Illinois CancerCare-Canton — Canton, Illinois
- Memorial Hospital of Carbondale — Carbondale, Illinois
- SIH Cancer Institute — Carterville, Illinois
- Illinois CancerCare-Carthage — Carthage, Illinois
Phase 3 Recruiting Industry
The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.
Sponsor: AstraZeneca
NCT ID: NCT06120491
Sites in Illinois: - Research Site — Glenview, Illinois
- Research Site — Lake Barrington, Illinois
Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of opevesostat plus hormone replacement therapy (HRT) compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136650
Sites in Illinois: - Edward-Elmhurst Healthcare, Elmhurst Hospital-Nancy W. Knowles Cancer Center ( Site 0074) — Elmhurst, Illinois
- Edward-Elmhurst Healthcare, Edward Hospital-Edward Cancer Center ( Site 0075) — Naperville, Illinois
- Illinois Cancer Care ( Site 0104) — Peoria, Illinois
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.
Sponsor: Celgene
NCT ID: NCT06764485
Sites in Illinois: - Northwestern Memorial Hospital — Chicago, Illinois
Phase 3 Recruiting Network
This study is being done to answer the following question: Is the strategy to give higher doses of radiotherapy treatment over a shorter period of time using special equipment and fewer treatments (also known as Stereotactic Body Radiation…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06235697
Sites in Illinois: - Memorial Hospital East — Shiloh, Illinois
Phase 3 Recruiting Industry
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136624
Sites in Illinois: - University of Illinois at Chicago ( Site 0105) — Chicago, Illinois
- University of Chicago Medical Center ( Site 0045) — Chicago, Illinois
Phase 3 Recruiting Industry
This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
Sponsor: Pfizer
NCT ID: NCT06629779
Sites in Illinois: - Accellacare of Duly — Lisle, Illinois
- Duly Health and Care (Bone Scintigraphy) — Lisle, Illinois
- Blessing Hospital — Quincy, Illinois
- Blessing Physician Services — Quincy, Illinois
- Duly Health and Care (CT and MRI) — Westmont, Illinois
Phase 3 Recruiting Industry
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in particip…
Sponsor: AstraZeneca
NCT ID: NCT06952803
Sites in Illinois: - Research Site — Chicago, Illinois
- Research Site — Chicago Ridge, Illinois
Phase 3 Recruiting Industry
The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans) when …
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07225946
Sites in Illinois: - Duly Health and Care — Lisle, Illinois
Phase 3 Recruiting Industry
The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).
Sponsor: Amgen
NCT ID: NCT07213674
Sites in Illinois: - University of Illinois Chicago — Chicago, Illinois
- City of Hope Chicago — Zion, Illinois
Phase 2, Phase 3 Recruiting Federal
This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival…
Sponsor: VA Office of Research and Development
NCT ID: NCT04787744
Sites in Illinois: - Edward Hines Jr. VA Hospital, Hines, IL — Hines, Illinois
Phase 3 Recruiting Network
The purpose of this study is to compare the effects, good and/or bad of two treatment methods on subjects and their cancer. Proton beam radiation therapy is one of the treatments for men with prostate cancer who have localized disease. The…
Sponsor: Proton Collaborative Group
NCT ID: NCT01492972
Sites in Illinois: - Northwestern Medicine Chicago Proton Center — Warrenville, Illinois
Phase 2 Recruiting Academic/Other
This phase II trial evaluates whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned. Patient cancer tissue samples are obtained from a previous surgery or biopsy procedure and tested …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06632977
Sites in Illinois: - Illinois CancerCare-Bloomington — Bloomington, Illinois
- Illinois CancerCare-Canton — Canton, Illinois
- Carle at The Riverfront — Danville, Illinois
- Carle Physician Group-Effingham — Effingham, Illinois
- Illinois CancerCare-Eureka — Eureka, Illinois
Phase 2 Recruiting Industry
A multicenter, open-label, prospective study to investigate immune boost response changes in patients with metastatic castrate-resistant prostate cancer (mCRPC).
Sponsor: Dendreon
NCT ID: NCT06134232
Sites in Illinois: - Associated Urological Specialists — Chicago Ridge, Illinois
- UroPartners — Glenview, Illinois
- Advanced Urology Associates — New Lenox, Illinois
Phase 2 Recruiting Industry
This Phase II study aims to evaluate efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg once a day (QD) doses + abiraterone compared with an androgen receptor pathway inhibitor (ARPI, abir…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06991556
Sites in Illinois: - Associated Urological Specialists — Chicago Ridge, Illinois
Phase 1, Phase 2 Recruiting Industry
This is a dose-finding study to assess the safety and preliminary antitumor activity of Pocenbrodib alone or with Abiraterone acetate, Olaparib or 177Lu-PSMA-617 in patients with metastatic castration-resistant prostrate cancer (mCRPC).
Sponsor: Pathos AI, Inc.
NCT ID: NCT06785636
Sites in Illinois: - University of Chicago — Chicago, Illinois
Phase 1, Phase 2 Recruiting Industry
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients with advanced solid tumors and lymphomas.
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT04104776
Sites in Illinois: - University of Chicago Medical Center — Chicago, Illinois
Phase 2 Recruiting Academic/Other
This study evaluates the efficacy, anti-tumor effect, and immunogenicity of neoadjuvant enoblituzumab given before radical prostatectomy. Patients will be randomized to enoblituzumab for a total of 12 weeks beginning 84 days before radical…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT06014255
Sites in Illinois: - Northewestern University — Chicago, Illinois
Phase 2 Recruiting Academic/Other
This is a multicenter, single-arm, two-stage open-label phase 2 study of the combination of cabozantinib + nivolumab in subjects with advanced castration-resistant prostate cancer (CRPC).
Sponsor: Rana McKay, MD
NCT ID: NCT05502315
Sites in Illinois: - University of Chicago Medical Center — Chicago, Illinois